Molecular Imaging

In a recent interview, Ashesh Jani, M.D., discussed pertinent findings in two post-hoc studies from the SPOTLIGHT trial that examined the efficacy of 18F-flotufolastat PET/CT for detecting biochemical recurrence and bone metastases in patients with prostate cancer.

Full approval of PNT2003, a radioequivalent of Lutathera (lutetium Lu 177 dotatate), is subject to a 30-month stay — triggered by a Hatch-Waxman patent litigation — that is reportedly set to expire in June 2026.

Catch up on the top radiology content of the past week.

In a recent interview, Brian Helfand, M.D., Ph.D., discussed key findings from a multicenter prospective trial, presented at the ASCO-GU symposium, that compared the PET radiotracers 18F-flotufolastat and 18F piflufolastat for urinary radioactivity and detection of PCa recurrence.

Catch up on the most-well viewed radiology content in February 2026.

In a recent interview from the ASCO-GU conference. Daniel George, M.D., discussed new study findings with 177Lu-PSMA-617 for the treatment of older taxane-naïve patients with metastatic castration-resistant prostate cancer (mCRPC) and potential implications for future research.

Catch up on the most well-viewed video interviews from Diagnostic Imaging in February 2026.

The AKY-1189 agent was designed for targeting of positive Nectin-4 expressing tumors that reportedly occur in 80 to 90 percent of patients with urothelial cancer.

Catch up on the top radiology content of the past week.

In comparison to 68Ga-PSMA-11, 64Cu-SAR-bisPSMA more than doubled the rate of detection for prostate cancer recurrence and facilitated changes to the treatment plan in 44 percent of patients, according to research to be presented at the upcoming European Association of Urology (EAU) Congress.

Catch up on the top radiology content of the past week.

The use of the SPECT/CT agent 99mTc-maraciclatide may enhance detection and differentiation for interstitial lung disease, which is associated with a large variety of disorders.

In a recent interview, Gary Ulaner, M.D., Ph.D., discussed preliminary research with the newly patented 61Cu-NU101 radiodiagnostic agent and the potential with the agent’s half-life in expanding access to molecular imaging for prostate cancer detection.

Researchers found that PSMA PET/CT offered 18 percent higher accuracy than mpMRI in detecting bilateral intraprostatic disease, according to a new study involving patients with intermediate or high-risk prostate cancer.

Catch up on the top radiology content of the past week.

A high SUVmean on PSMA PET imaging was associated with 95 more days of mean progression-free survival (PFS) in contrast to those with a low median SUVmean, according to a new study of patients with mCRPC treated with (225Ac)Ac-PSMA-I&T.

Catch up on the top radiology content of the past week.

The Biograph One PET/MRI system may facilitate accelerated scan times, improved visualization and more efficient assessments of theranostic approaches for patients with oncologic and neurological diseases.

Catch up on the most-well viewed radiology content in January 2026.

Employing AI-powered automation, the MIM LesionID™ Pro reportedly bolsters the efficiency of whole-body tumor burden analysis with PSMA PET/CT and SPECT/CT.

In recent interviews, Rajesh Bhayana, M.D., Manisha Bahl, M.D., and Jeremie Calais, M.D., Ph.D., shared their thoughts on agentic AI, key directions in breast imaging research and emerging trends with prostate cancer theranostics in 2026.

Catch up on the top radiology content of the past week.

The upgraded RefleXion X2 platform offers a 20 cm field of view that may bolster visualization of moving tumors.

In a recent interview, Onofrio Catalano, M.D., Ph.D., discussed new research findings demonstrating robust sensitivity and specificity in detecting hepatocellular carcinoma in patients with LI-RADS 3 presentations.

In a recent interview, Jeremie Calais, M.D., Ph.D., discussed new research examining the prognostic capacity of PSMA PET parameters in predicting hematologic toxicity and outcomes for patients treated with (177Lu)Lu-PSMA-617 for mCRPC.